Physician profile
Lydia V Wallace
NPI 1215139381
$1,638.24
in general payments reported to CMS, 2019-2025
23 companies · $675 in 2025
The $675 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $483 · 2023: $288 · 2024: $192 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $310.28 | 2022-2025 | |
| Glaxosmithkline, LLC. | $183.16 | 2022-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $182.56 | 2022-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $164.05 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.28 | 2025 | Caplyta |
| Boston Scientific Corporation | $115.47 | 2024-2025 | Watchman Flx |
| Lilly USA, LLC | $77.54 | 2022-2025 | Jardiance, Mounjaro |
| Esperion Therapeutics, INC. | $63.88 | 2025 | Nexletol |
| Amgen INC. | $63.64 | 2024-2025 | Repatha, Otezla, Otezla |
| Scpharmaceuticals INC. | $51.91 | 2025 | |
| Abbvie INC. | $47.44 | 2025 | |
| Amarin Pharma, INC. | $35.36 | 2022 | |
| Phathom Pharmaceuticals, INC. | $35.01 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $33.75 | 2022 | |
| Lundbeck LLC | $22.44 | 2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21.71 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $19.45 | 2022 | |
| Abbott Laboratories | $18.54 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.76 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.67 | 2022 | |
| Mylan Specialty L.P. | $14.54 | 2023 | Yupelri |
| Astellas Pharma US INC | $13.41 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.